- Home
- SPPL vs PHGE Comparison
SPPL vs PHGE Comparison
Compare SPPL & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPL
- PHGE
- Stock Information
- Founded
- SPPL 2016
- PHGE 2015
- Country
- SPPL Singapore
- PHGE Israel
- Employees
- SPPL N/A
- PHGE N/A
- Industry
- SPPL
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- SPPL
- PHGE Health Care
- Exchange
- SPPL Nasdaq
- PHGE Nasdaq
- Market Cap
- SPPL 10.4M
- PHGE 11.0M
- IPO Year
- SPPL 2023
- PHGE N/A
- Fundamental
- Price
- SPPL $2.71
- PHGE $0.44
- Analyst Decision
- SPPL
- PHGE Strong Buy
- Analyst Count
- SPPL 0
- PHGE 1
- Target Price
- SPPL N/A
- PHGE $15.00
- AVG Volume (30 Days)
- SPPL 11.9K
- PHGE 290.5K
- Earning Date
- SPPL 01-01-0001
- PHGE 08-13-2025
- Dividend Yield
- SPPL N/A
- PHGE N/A
- EPS Growth
- SPPL N/A
- PHGE N/A
- EPS
- SPPL N/A
- PHGE N/A
- Revenue
- SPPL $2,764,846.00
- PHGE N/A
- Revenue This Year
- SPPL N/A
- PHGE N/A
- Revenue Next Year
- SPPL N/A
- PHGE N/A
- P/E Ratio
- SPPL N/A
- PHGE N/A
- Revenue Growth
- SPPL N/A
- PHGE N/A
- 52 Week Low
- SPPL $2.02
- PHGE $0.34
- 52 Week High
- SPPL $16.80
- PHGE $3.86
- Technical
- Relative Strength Index (RSI)
- SPPL 44.29
- PHGE 43.34
- Support Level
- SPPL $2.56
- PHGE $0.43
- Resistance Level
- SPPL $2.94
- PHGE $0.50
- Average True Range (ATR)
- SPPL 0.22
- PHGE 0.05
- MACD
- SPPL 0.02
- PHGE 0.00
- Stochastic Oscillator
- SPPL 26.50
- PHGE 58.82
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).